CorInnova

Executive Summary

CorInnova is developing a minimally invasive, non-blood contacting cardiac assist device for acute heart failure, addressing the large and growing short-term cardiac assist market (up to 5 days). With lead investment from Wellcome Trust, the company's collapsible device expands the addressable market to $5B by enabling treatment for the 50% of patients unsuitable for existing devices. The device is designed for ease of deployment and reduced complications, potentially transforming acute heart failure management. Currently in Phase 1/2 clinical stage, CorInnova aims to bridge the gap between medical therapy and more invasive support systems. The company's technology has garnered interest due to its novel approach and significant market potential, though it remains early-stage with regulatory and clinical execution risks.

Upcoming Catalysts (preview)

• Q4 2026Initiation of pivotal clinical trial70% success
• Q2 2026FDA Breakthrough Device designation60% success
• H1 2027Strategic partnership or licensing deal with major medtech company50% success